Use of Articles in the Pachyonychia Congenita Bibliography

The articles in the PC Bibliography may be restricted by copyright laws. These have been made available to you by PC Project for the exclusive use in teaching, scholarship or research regarding Pachyonychia Congenita.

To the best of our understanding, in supplying this material to you we have followed the guidelines of Sec 107 regarding fair use of copyright materials. That section reads as follows:

Sec. 107. - Limitations on exclusive rights: Fair use
Notwithstanding the provisions of sections 106 and 106A, the fair use of a copyrighted work, including such use by reproduction in copies or phonorecords or by any other means specified by that section, for purposes such as criticism, comment, news reporting, teaching (including multiple copies for classroom use), scholarship, or research, is not an infringement of copyright. In determining whether the use made of a work in any particular case is a fair use the factors to be considered shall include - (1) the purpose and character of the use, including whether such use is of a commercial nature or is for nonprofit educational purposes; (2) the nature of the copyrighted work; (3) the amount and substantiality of the portion used in relation to the copyrighted work as a whole; and (4) the effect of the use upon the potential market for or value of the copyrighted work. The fact that a work is unpublished shall not itself bar a finding of fair use if such finding is made upon consideration of all the above factors.

We hope that making available the relevant information on Pachyonychia Congenita will be a means of furthering research to find effective therapies and a cure for PC.
Response to the Commentary “Significance of Patient Registries for Dermatological Disorder”

TO THE EDITOR

We were pleased to see the commentary “Significance of Patient Registries for Dermatological Disorder” by Dr de Souza and Ms Miller (2012). Registries are vital for teasing out complexities of dermatologic disorders, especially rare dermatologic diseases. The authors highlighted the need for patient registries, as well as some of the challenges associated with them (e.g., inadequate standards, lack of adherence to standards, funding challenges, and so on). We appreciate the authors’ acknowledgment of advocacy-led registries. Advocacy organizations are playing an increased role in clinical research, including involvement in registries and biobanks (Terry et al., 2007; Landy et al., 2012). Whereas some foundation-led registries are designed for advocacy, educational, or fundraising purposes as noted by the authors, many foundations have developed registries to further the natural history and epidemiologic understanding of specific conditions.

The Pseudoxanthoma Elasticum International Registry (www.pxe.org) collects donor-reported epidemiological data and has a corresponding biobank of DNA and tissue samples. The National Psoriasis Foundation (www.psoriasis.org) also has a US-focused registry and biobank with corresponding DNA samples. (The pseudoxanthoma elasticum and psoriasis registries were not included in the selected patient registries in dermatologic disorders). These organizations, together with the US Hereditary Angioedema Association (www.haea.org), are all members of Genetic Alliance Registry & BioBank, a cooperative model to share infrastructure and expertise across member organizations (Terry et al., 2011). The three registries mentioned above, similar to many registries, are funded by the advocacy organizations that run them (the article erroneously lists industry funding for the HAEA scientific registry). In the commentary, the Cystic Fibrosis (CF) Registry is identified as a gold standard. It would be of benefit to the readership to identify areas in which each registry listed in the article matches or exceeds the CF registry. For example, the International Pachyonychia Congenita Registry offers free genetic testing to all participants, and serves patients in 50+ countries in seven languages (Irvine, 2012). Although this is just one example, there are likely numerous successes from the other registries listed and those not included.

The current system of academic research and rewards is fractured and unable to facilitate true collaboration and sharing. This is not sustainable, and as a community we have the opportunity and the obligation to improve the biomedical ecosystem. It is clear that advocacy organizations, individual advocates, and citizen scientists are essential partners for transforming the system. Advocacy organizations are vital partners for registries and biobanks, as they are poised to develop communities of trust and leverage scarce resources. They understand the unmet research needs of the community, can facilitate collaboration between diverse stakeholders, and are appropriate and dedicated stewards of data and samples.

We encourage providers, researchers, industry, and advocacy organizations to work together to make these resources as strong as they can be. We also thank the authors for reminding the scientific community how important patient registries are for dermatologic disorders.

Liz Horn1, Marin Aurand2, Mary E. Schwartz3 and Sharon F. Terry1
1Genetic Alliance, Washington, District Of Columbia, USA; 2National Psoriasis Foundation, Portland, Oregon, USA and 3Pachyonychia Congenita Project, Salt Lake City, Utah, USA
E-mail: sterry@geneticalliance.org

REFERENCES

Terry SF, Terry PF, Rauen KA et al. (2007) Advocacy groups as research organizations: the PXE International example. Nat Rev Genet 8:157–64

Abbreviation: CF, cystic fibrosis